Shares of Advaxis, Inc. (NASDAQ:ADXS) shot up 8.7% on Tuesday . The company traded as high as $0.52 and last traded at $0.50, 844,381 shares traded hands during mid-day trading. An increase of 116% from the average session volume of 391,184 shares. The stock had previously closed at $0.46.
A number of research firms have weighed in on ADXS. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Advaxis from a “hold” rating to a “sell” rating in a research note on Monday, July 29th. Finally, HC Wainwright restated a “neutral” rating on shares of Advaxis in a research note on Wednesday, June 12th.
The stock’s 50 day moving average is $1.46. The company has a market cap of $8.34 million, a PE ratio of -0.03 and a beta of 3.23.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its position in shares of Advaxis by 2,468.2% in the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 355,415 shares during the last quarter. BlackRock Inc. lifted its position in shares of Advaxis by 3.1% in the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 43,368 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 553,031 shares during the last quarter. 16.73% of the stock is owned by institutional investors.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Further Reading: How to build a Fibonacci channel
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.